- Dutch biotech Leyden Labs has raised a 30 million euro equity investment from the European Innovation Council (EIC) Fund and Invest-NL to accelerate the development of its PanFlu nasal spray.
- The support from the EIC Fund and Invest-NL helps strengthen Europe's preparedness against current and future viral threats.
- This strategic investment further builds out the global syndicate of investors in Leyden Labs.
LEIDEN, the Netherlands, October 2, 2025 - Dutch biotech Leyden Laboratories B.V. today announced 30 million euros in new equity financing from the European Innovation Council (EIC) Fund and Invest-NL.
"The COVID-19 pandemic has underlined the critical importance of Europe's preparedness for future health crises," said Svetoslava Georgieva, Chair of the EIC Fund Board.
"As the Dutch national promotional institution, we are proud to support Leyden Labs in its mission to stop respiratory viruses at the gate," said Ineke Cazander, investment principal at Invest-NL.
"With PanFlu, we are taking a bold step to stop influenza viruses at the gate," said Koenraad Wiedhaup, co-founder and CEO of Leyden Labs.
"These latest investments build on the significant momentum in our fundraising efforts this year, including our $70 million Series B announced in January and recent 20 million euro EIB venture debt investment," said Marieke van der Lans, CFO of Leyden Labs.
About Leyden Laboratories B.V.
Founded in 2020, a clinical-stage biotechnology company based in the Netherlands. Investors include GV, Casdin Capital, F-Prime Capital, ClavystBio, Polaris Partners, Qiming Venture Partners, Invus, SoftBank Vision Fund 2, Byers Capital / Brook Byers and Bluebird Ventures. To learn more, visit www.leydenlabs.com.
Media and Investor Contacts
Leyden Labs Media Contact: Megan Prock McGrath, CTD Comms, LLC, +1 978-800-7468, media@leydenlabs.com
Leyden Labs Investor Contact: Elizabeth Goodwin, +1 781-460-1784, investors@leydenlabs.com
